Mix-and-match vaccines highly effective against Covid: Lancet study

Since the use of AstraZeneca's vector-based vaccine against Covid was halted for people younger than 65 due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose

Mix-and-match vaccines highly effective against Covid: Lancet study

Photo for representation purposes.

London, October 18

People who received a first dose of the Oxford-AstraZeneca Covid vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden.

Since the use of AstraZeneca's vector-based vaccine against Covid was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.

"Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one," said Peter Nordstrom, a professor at Umea University, Sweden.

"However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses," Nordstrom said.

The study, published in The Lancet Regional Health - Europe journal on Monday, is based on nationwide registry data from the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden.

In the main analysis, about 700,000 individuals were included. During a 2.5-month average follow-up period after the second dose, the study showed a 67 per cent lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots.

There was a 79 per cent lower risk of infection for AstraZeneca and Moderna vaccine shots, compared to unvaccinated individuals, the researchers said.

For people having received two doses of the AstraZeneca vaccine, known as Covishield in India, the risk reduction was 50, they said.

These risk estimates were observed after accounting for differences regarding date of vaccination, age of the participants, socioeconomic status, and other risk factors for Covid.

The researchers noted that the study estimates of effectiveness apply to infection with the Delta variant, which was dominating the confirmed cases during the follow-up period.

"The results of the study may have implications for vaccination strategies in different countries," said Marcel Ballin, doctoral student at Umea University, and co-author of the study. PTI

Tribune Shorts


Top Stories

NDA finalises alliance with Apna Dal, Nishad Party

Uttar Pradesh polls: BJP finalises seat-sharing with Apna Dal and Nishad Party

Leaders did not give numbers but said that the three parties...

Govt expert panel recommends regular market approval for Covishield, Covaxin

Govt expert panel recommends regular market approval for Covishield, Covaxin

Covaxin and Covishield were granted Emergency Use Authorisat...

IndiGo planes avert mid-air collision over Bengaluru airport; DGCA to probe, take strict action

IndiGo planes avert mid-air collision over Bengaluru airport; DGCA to probe, take strict action

The incident occurred on January 9; not logged in any logboo...

5G scare: Air India cancels 8 US flights; DGCA working to overcome situation

5G scare: Air India cancels 8 US flights; DGCA working to overcome situation

US aviation regulator had on January 14 said '5G interferenc...

DGCA extends suspension of scheduled international passenger flights till February 28

DGCA extends suspension of scheduled international passenger flights till February 28

Scheduled international passenger flights have been suspende...

Cities

View All